Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Lamarca

Showing results (151-160 of 201) with videos related to

Pageof 21
Sort By:
The Journal of Clinical Endocrinology and Metabolism|July 27, 2016
Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine TumorsOmid Fotouhi, Hanna Kjellin, Catharina Larsson, et al.
World Journal of Clinical Oncology|May 2, 2020
Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumoursJaseela Chiramel, Rose Almond, Astrid Slagter, et al.
Acta Oncologica (Stockholm, Sweden)|April 8, 2022
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapyKonstantinos Kamposioras, George Papaxoinis, Mohamed Dawood, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 26, 2021
Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysisJames M Halle-Smith, Lewis Hall, Lois A Daamen, et al.
Nature Communications|December 18, 2021
Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasisBrian Y Lee, Elizabeth K J Hogg, Christopher R Below, et al.
Future Oncology (London, England)|June 26, 2020
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, et al.
BMJ Open|October 26, 2022
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literatureMairéad G McNamara, John Bridgewater, Lipika Goyal, et al.
World Journal of Gastroenterology|October 30, 2019
Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centresMelissa Frizziero, Xin Wang, Bipasha Chakrabarty, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
Scientific Reports|August 14, 2019
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancerSumitra Mohan, Mahmood Ayub, Dominic G Rothwell, et al.
Pageof 21

Showing results (151-160 of 201) with videos related to

Sort By:
Pageof 21
The Journal of Clinical Endocrinology and Metabolism|July 27, 2016
Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine TumorsOmid Fotouhi, Hanna Kjellin, Catharina Larsson, et al.
World Journal of Clinical Oncology|May 2, 2020
Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumoursJaseela Chiramel, Rose Almond, Astrid Slagter, et al.
Acta Oncologica (Stockholm, Sweden)|April 8, 2022
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapyKonstantinos Kamposioras, George Papaxoinis, Mohamed Dawood, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 26, 2021
Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysisJames M Halle-Smith, Lewis Hall, Lois A Daamen, et al.
Nature Communications|December 18, 2021
Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasisBrian Y Lee, Elizabeth K J Hogg, Christopher R Below, et al.
Future Oncology (London, England)|June 26, 2020
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, et al.
BMJ Open|October 26, 2022
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literatureMairéad G McNamara, John Bridgewater, Lipika Goyal, et al.
World Journal of Gastroenterology|October 30, 2019
Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centresMelissa Frizziero, Xin Wang, Bipasha Chakrabarty, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
Scientific Reports|August 14, 2019
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancerSumitra Mohan, Mahmood Ayub, Dominic G Rothwell, et al.
Pageof 21